Biogen (NASDAQ:BIIB) Announces Earnings Results, Beats Expectations By $0.01 EPS

Biogen (NASDAQ:BIIB) posted its earnings results on Wednesday. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01, Zacks reports. Biogen had a net margin of 16.81% and a return on equity of 14.98%. Biogen updated its FY 2025 guidance to 15.250-16.250 EPS.

Biogen Stock Down 2.2 %

BIIB stock opened at $139.39 on Wednesday. The company has a fifty day moving average price of $148.28 and a 200 day moving average price of $174.33. Biogen has a 12 month low of $138.72 and a 12 month high of $244.95. The company has a market cap of $20.31 billion, a price-to-earnings ratio of 12.59, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BIIB shares. Robert W. Baird upped their price target on shares of Biogen from $294.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. Wells Fargo & Company cut their price target on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Stifel Nicolaus lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 price target on the stock. in a research note on Monday, December 16th. Bank Of America (Bofa) cut their price target on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Mizuho cut their price target on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Seventeen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $221.65.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.